In ₹ Crore except Per Share Latest Annual	SHREECEM FY26	ULTRACEMCO FY26	AMBUJACEM FY26	ACC FY26	Peer Average
Valuation — at last close
P/E	47.08×	39.28×	18.77×	◆ 10.22×	22.76× +107%
P/B	3.53×	4.19×	1.50×	◆ 1.06×	2.25× +57%
EV/EBITDA	16.18×	20.16×	15.36×	◆ 7.23×	14.25× +14%
Market Cap	₹82,082 Cr	₹3.21L Cr	₹88,861 Cr	₹21,871 Cr	₹1.44L Cr -43%
Growth
Revenue CAGR 3Y	5.47%	◆ 11.86%	1.45%	5.34%	6.22% -12%
Revenue CAGR 5Y	9.22%	◆ 14.63%	7.02%	9.96%	10.54% -12%
Net Income CAGR 3Y	11.28%	17.30%	23.07%	◆ 34.15%	24.84% -55%
Revenue YoY (latest Q)	◆ 23.85%	18.81%	0.25%	-4.09%	4.99% +378%
Net Income YoY (latest Q)	-14.96%	◆ 21.28%	-89.75%	-91.69%	-53.39% +72%
Profitability
EBITDA Margin	◆ 22.14%	19.23%	16.08%	11.36%	15.56% +42%
Net Income Margin	8.35%	9.25%	◆ 13.87%	8.23%	10.45% -20%
Return on Common Equity	7.78%	◆ 11.08%	8.38%	10.93%	10.13% -23%
Return on Capital Employed	7.81%	◆ 11.85%	4.13%	8.83%	8.27% -6%
Return on Assets	5.83%	5.95%	6.61%	◆ 8.07%	6.88% -15%
Credit & Quality
Total Debt/Equity	0.07×	0.28×	◆ 0.00×	0.00×	0.09× -25%
Interest Coverage	8.71×	6.61×	13.28×	◆ 16.35×	12.08× -28%
Scale — latest FY
Revenue / Total Income	₹20,943 Cr	₹88,512 Cr	₹40,656 Cr	₹25,962 Cr	₹51,710 Cr -59%
Net Income	₹1,749 Cr	₹8,188 Cr	₹5,637 Cr	₹2,137 Cr	₹5,321 Cr -67%
Total Assets	₹31,476 Cr	₹1.41L Cr	₹89,607 Cr	₹27,525 Cr	₹86,169 Cr -63%
EPS	₹483.24	₹277.62	₹19.15	₹113.8	₹136.86 +253%
Book Value per Share	₹6,448.87	₹2,600.23	₹240.1	₹1,093.17	₹1,311.17 +392%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.